Next Science Ltd (NXS) AI Stock Analysis

• Market Cap: AU$43.89M
• Dividend Yield: N/A
• Average Volume (3M): 213.35K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.92
• Revenue Growth: -4.27%
• EPS Growth: 33.91%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.02
• Shares Outstanding: 292,625,370
• 10 Day Avg. Volume: 86,850
• 30 Day Avg. Volume: 213,352
• PEG Ratio: 0.04
• Price to Book (P/B): 6.03
• Price to Sales (P/S): 0.91
• P/FCF Ratio: -2.43
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.04
• Revenue Forecast (FY): AU$62.42M

• Rating: 48 Neutral
• Price Target: AU$0.00 ▼(-100.00% Downside)

Next Science Ltd's overall stock score is primarily impacted by its challenging financial performance, with persistent losses and negative cash flows. While technical analysis indicates positive momentum, the valuation remains unattractive due to negative earnings and lack of dividends. The absence of earnings call and corporate events data limits further insights.

Next Science Ltd Business Overview & Revenue Model

Company Description

Next Science Ltd (NXS) is a biotechnology company based in Australia that specializes in developing innovative solutions for the treatment of chronic wounds and biofilm-related infections. The company operates primarily in the healthcare sector, focusing on advancing its proprietary Xbio technology platform, which disrupts biofilm and promotes healing in various medical applications. Next Science's core products include its wound care and sinus healthcare offerings, which are designed to improve patient outcomes and reduce the need for antibiotics.

How the Company Makes Money

Next Science generates revenue through the sale of its medical products, particularly those related to wound care and sinus health. The company markets its products directly to healthcare providers, hospitals, and clinics, leveraging both direct sales and distribution partnerships. Key revenue streams include product sales from its wound care line, which includes advanced dressings and topical solutions, as well as its sinus products aimed at addressing chronic sinusitis. Additionally, Next Science may engage in collaborations or partnerships with larger pharmaceutical companies, allowing for shared resources and expanded market reach, which can further enhance its earnings potential. The company also benefits from intellectual property rights associated with its proprietary technologies, which may provide licensing opportunities and contribute to its revenue.

Next Science Ltd Financial Statement Overview

Summary

Next Science Ltd is facing financial difficulties with persistent losses and negative cash flows. Despite modest revenue growth, the company struggles with severe profitability challenges, as indicated by negative margins and a strained balance sheet.

Income Statement

Next Science Ltd has experienced growth in revenue from 2023 to 2024, with a revenue growth rate of 2.87%. However, the company is facing significant challenges in profitability as indicated by negative EBIT and EBITDA margins. The net profit margin remains negative, highlighting ongoing losses and indicating the company is struggling to cover its operational costs.

Balance Sheet

The balance sheet reveals a strained financial position with a debt-to-equity ratio of 0.72, suggesting moderate leverage but reduced equity base. The return on equity is deeply negative at -307.61%, reflecting substantial losses relative to shareholder equity. The equity ratio stands at 37.37%, indicating a relatively balanced capital structure but a decline from previous years.

Cash Flow

Next Science Ltd's cash flow indicates operational challenges with negative operating and free cash flows. The free cash flow to net income ratio is negative, showing cash outflows persist. There is no positive cash flow growth, implying potential liquidity issues and limited cash generation capability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	16.82M	22.82M	22.18M	11.71M	8.95M	3.44M
Gross Profit	13.84M	18.44M	16.23M	11.90M	5.94M	2.47M
EBITDA	-6.17M	-9.03M	-14.42M	-12.25M	-9.22M	-11.83M
Net Income	-7.09M	-10.59M	-24.51M	-18.30M	-9.35M	-11.91M
Balance Sheet
Total Assets	9.46M	9.21M	17.90M	18.37M	13.67M	23.49M
Cash, Cash Equivalents and Short-Term Investments	971.24K	1.67M	9.28M	5.11M	7.35M	15.34M
Total Debt	5.30M	2.49M	961.97K	1.22M	275.19K	286.83K
Total Liabilities	10.02M	5.77M	5.08M	6.52M	2.94M	4.70M
Stockholders Equity	-557.03K	3.44M	12.82M	11.85M	10.73M	18.80M
Cash Flow
Free Cash Flow	-4.35M	-8.55M	-15.94M	-17.69M	-8.67M	-14.03M
Operating Cash Flow	-4.32M	-7.96M	-15.06M	-17.01M	-7.98M	-13.26M
Investing Cash Flow	-412.02K	-589.22K	-884.50K	-475.72K	-716.76K	-686.80K
Financing Cash Flow	2.12M	1.75M	20.11M	10.25M	1.43M	10.71M

Next Science Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.15
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NXS, the sentiment is Positive. The current price of 0.15 is below the 20-day moving average (MA) of 0.15, above the 50-day MA of 0.15, and above the 200-day MA of 0.12, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.87 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:NXS.

Next Science Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIT	59 Neutral	AU$41.75M	11.67	7.64%	3.23%	0.13%	-12.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NXS	48 Neutral	AU$43.89M	―	-289.70%	―	-4.27%	33.91%
MVP	46 Neutral	AU$77.73M	690.00	0.19%	―	17.82%	―
AGH	41 Neutral	AU$19.03M	-1.28	―	―	-47.30%	82.53%
IDT	39 Underperform	AU$24.81M	-3.16	-35.58%	―	45.30%	-24.18%

Next Science Ltd Corporate Events

Next Science Ltd Announces Cessation of Securities

Next Science Ltd announced the cessation of certain securities, including sign-on rights, options, and performance rights, due to unmet conditions. This development may impact the company’s capital structure and could influence stakeholder perceptions regarding the company’s financial strategies and operational focus.

The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.

Next Science Completes Major Asset Sale to OSARTIS

Next Science Limited has completed the sale of most of its assets to OSARTIS GmbH for $50 million, with plans to distribute approximately $30 million in net proceeds to shareholders after settling debts and costs. The company has also established transitional agreements to ensure a smooth separation and will seek shareholder approval for the distribution method in a meeting expected to be announced in November 2025.

The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.

Next Science Reports Decline in Sales and Asset Sale Approval

Next Science Limited reported its half-year financial results for the period ending June 30, 2025, showing a 7% decline in product sales to US$10.5 million. Despite a 54% increase in direct sales of XPERIENCE, overall direct product sales fell by 20%. The company improved its operating expenses by 17%, resulting in a reduced adjusted EBITDA loss of US$2.8 million. The shareholders approved the sale of the majority of the Group’s assets to OSARTIS GmbH, expected to complete by mid-September 2025, which will not affect the company’s capital structure.

The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.

Next Science Reports Revenue Decline but Reduces Losses in H1 2025

Next Science Limited reported a 7% decrease in revenues for the half-year ended June 30, 2025, amounting to USD 10,491,366. Despite the decline in revenue, the company managed to reduce its loss from ordinary activities by 20%, bringing it down to USD 4,687,973. No dividends were paid or proposed during this period. The net tangible assets per ordinary security also saw a decline, moving from 1.62 USD cents in the previous period to -0.84 USD cents in the current reporting period. This financial performance indicates challenges in maintaining revenue growth, yet shows some progress in cost management.

The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.

Next Science Limited Announces Successful Resolution at General Meeting

Next Science Limited announced the results of its General Meeting, where the resolution proposed was passed by the required majority through a poll. This outcome aligns with ASX Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001. The successful passing of the resolution is a significant step for the company, potentially impacting its operational strategies and strengthening its position in the medical technology industry.

The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.

Next Science Announces Change in Asset Purchase Agreement

Next Science Limited has announced an addendum to its Notice of General Meeting, detailing a change in the purchaser of its assets from Demetra Holding S.p.A to OSARTIS GmbH, a portfolio company of Demetra. This change does not affect the fairness and reasonableness of the proposed transaction as confirmed by the Independent Expert’s Report. The meeting details remain unchanged, and shareholders can alter their proxy votes online if needed.

The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.

Next Science Reports Decline in Q2 Sales Amid Strategic Moves

Next Science Limited reported a 10% decline in product sales for the second quarter of FY25 compared to the previous year, with sales totaling US$5.2 million. Despite strong growth in direct sales of XPERIENCE and BLASTX, the company faced challenges in the Durable Medical Equipment (DME) channel, impacting overall sales. The company also announced a binding asset purchase agreement with Demetra Holdings S.p.A., subject to shareholder approval, which could influence its market positioning and operations.

The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.

Next Science Announces General Meeting for Major Asset Sale

Next Science Limited has announced a General Meeting scheduled for August 28, 2025, to discuss the proposed asset purchase agreement with Demetra, which involves the sale of Next Science’s main undertaking. This transaction requires shareholder approval as per Listing Rule 11.2, and the meeting will be conducted both in-person and virtually. The outcome of this meeting could significantly impact the company’s operations and market positioning, as it involves a major asset sale.

The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.